Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition

Vojnosanitetski Pregled

Volumn 66, Issue 7, 2009, Pages 556-562

  Janković, Slobodan M ^a,b   Kostić, Marina ^a   Radosavljević, Marija ^a   Tešić, Danka ^a   Stefanović Stoimenov, Nataša ^a   Stevanović, Ivan ^a   Raković, Slacrossed D Signana ^a   Aleksić, Jelena ^a   Folić, Marko ^a   Aleksić, Aleksandra ^a   Mihajlović, Ivana ^a   Biorac, Nenad ^a   Borlja, Jelena ^a   Vučković, Radosava ^a  

^a Medical Faculty   (Serbia)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

Cost and analysis; Imunologic factors; Multiple sclerosis; Treatment outcome; Yugoslavia

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ARTICLE; CALCULATION; COST EFFECTIVENESS ANALYSIS; HUMAN; IMMUNOMODULATION; MODEL; MONTE CARLO METHOD; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RELAPSING REMITTING MULTIPLE SCLEROSIS; SOCIAL ASPECT; SOCIOECONOMICS;

EID: 68249132314     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP0907556J     Document Type: Article

References (24)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221-1231
2. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007; 256 Suppl 1: S5-13. (Pubitemid 46560640)
3. Pekmezovic T, Jarebinski M, Drulovic J, Stojsavljevic N, Levic Z. Prevalence of multiple sclerosis in Belgrade, Yugoslavia. Acta Neurol Scand 2001; 104(6): 353-357 (Pubitemid 33105107)
4. Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry 2001; 70(5): 574-579
5. Jankovic SM, Milivojevic N. National-level purchasing of expensive drugs is increasing pressure on the hospital drug budget. Pharmacoeconomics 2006; 24(8): 831-832 (Pubitemid 44232109)
6. Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6(10): 1-73. (Pubitemid 34552394)
7. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7(10): 903-914
8. Iskedjian M, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event. Mult Scler 2005; 11(5): 542-551 (Pubitemid 41387699)
9. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002; 5(1): 44-54. (Pubitemid 34160370)
10. The World Bank. Data & Statistics. [Accessed the last time on 2008 August 26]. Available from: http://web.worldbank.org./WBSITE/EXTERNAL/ DATASTATISTICS/0.
11. World Health Organization Statistical Information System (WHOSIS). Core Health Indicators. [Accessed the last time on 2008 August 26]. Available from: http://www.who.int./whosis/database/core/
12. Anonymous. Tariff Book of Health Care Services in Health Facilities of Republic of Serbia. Belgrade: Republic Institute for Health Insurance; 2008.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452
14. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007; 13(3): 245-261 (Pubitemid 46730893)
15. Managig board of Republic Institute for Health Insurance. Directive on list of drugs which are prescribed and dispensed on account of mandatory health insurance. Official Gazzete of Republic of Serbia 2007; 63(127): 16-217.
16. Employment and Earnings Statistics. Available at: http://www.webrzs.stat. gov.rs./,and/en/prpub.php#10
17. TreeAge Pro, Healthcare software. Release 0.78, 2005; 1988-2005 TreeAge Software Inc. Available form: http://www.treeage.com
18. Prosser LA, Kuntz KM, Abr-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004; 7(5): 554-568
19. Employment and Earnings Statistics. Statistical Office of the Republic of Serbia. [Accessed the last time on 2008 October 18]. Available from:webrzs.statserb.sr.gov.yu/axd/en/index.
20. TreeAge Pro. Healthcare software. TreeAge Software Inc. [release 2005; 1988-2005]. Available from: www.softscout.com/software/Healthcare-and-Human- Services/Diagnosis
21. Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004; 7(5): 554-568 (Pubitemid 39390836)
22. Clegg A, Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001; 2(4): 623-639 (Pubitemid 32427757)
23. Rieckmann P, Toyka KV. Multiple Sclerosis Therapy Consensus Group. Immunomodulatory staged therapy of multiple sclerosis. New aspects and practical applications, March 2002. Nervenarzt 2002; 73(6): 556-563 (German)
24. Jakovljevic M, Varjacic M, Jankovic SM. Cost-effectiveness of ritodrine and fenoterol for treatment of preterm labor in a low-middle-income country: a case study. Value Health 2008; 11(2): 149-153